Dimitrios-ilias Balourdas

Max Von Laue Str. 15
Frankfurt Am Main, HE 60438, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants.

DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 28, 2026

Highlights from the Windy City: Early Career Medicinal Chemists Experiences at Medicinal Chemistry Frontiers 2025.

Highlights from the Windy City: Early Career Medicinal Chemists Experiences at Medicinal Chemistry Frontiers 2025.

Journal: Journal of medicinal chemistry

Published: February 13, 2026

Horizon scanning at EMA: preparing for the medicines of the future.

Horizon scanning at EMA: preparing for the medicines of the future.

Journal: Frontiers in medicine

Published: January 30, 2026

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

Journal: Cell death & disease

Published: August 12, 2025

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.

Journal: Journal of medicinal chemistry

Published: April 17, 2025

Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε.

Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε.

Journal: Journal of medicinal chemistry

Published: May 23, 2024

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.

Journal: Nature genetics

Published: March 17, 2024

Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.

Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: February 29, 2024

DARPin-induced reactivation of p53 in HPV-positive cells.

DARPin-induced reactivation of p53 in HPV-positive cells.

Journal: Nature structural & molecular biology

Published: February 01, 2024

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.

Journal: ACS chemical biology

Published: January 31, 2024

Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3.

Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3.

Journal: Journal of medicinal chemistry

Published: December 21, 2023

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.

Journal: Cell death & disease

Published: December 13, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026